Published 18 hours ago • loading... • Updated 17 hours ago

SCG Announces Late-Breaking Clinical Data of SCG101 in HBV-Related Hepatocellular Carcinoma Presented at EASL 2025

On May 7, 2025, SCG Cell Therapy, a Singapore-based biotechnology company, announced late-breaking Phase 1 clinical data for SCG101 in advanced HBV-related hepatocellular carcinoma patients in Singapore.
The announcement followed a heavily pre-treated patient population, including 94% with prior antiviral therapy and 72% with liver cirrhosis, reflecting the advanced stage of HBV-related liver cancer.
A single infusion of SCG101, a personalized TCR-T cell treatment targeting HBV, resulted in sustained reductions in serum HBsAg and HBV-DNA levels, with nearly half of the patients showing measurable tumor shrinkage and the therapy being well tolerated.
After a single infusion of SCG101, 94% of patients showed a 1.0–4.6 log reduction in HBsAg levels within 28 days, with 23.5% achieving complete loss of HBsAg; additionally, transient elevations in ALT were noted in 94% of patients but returned to baseline within two weeks.
These findings suggest SCG101 offers a novel immunotherapy combining antiviral and antitumor effects for HBV-related HCC, addressing a major unmet need with further clinical development planned.

Insights by Ground AI

Does this summary seem wrong?

48 Articles

All

Left

Center

Right

The Berkshire Eagle

+47 Reposted by 47 other sources

Center

SCG Announces Late-Breaking Clinical Data of SCG101 in HBV-Related Hepatocellular Carcinoma Presented at EASL 2025

SINGAPORE, May 7, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from its Phase 1 trial evaluating SCG101, autologous…

18 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year